A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

NCT06593587 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

378

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL: RSVpreF Vaccine
OTHER: Placebo

Sponsor

Pfizer